Investigational Drug for to treat Metastatic Pancreatic Ductal Adenocarcinom
Darren Sigal, M.D.
This is a double blind, phase 3 trial to evaluate the effectiveness of the Investigational Drug PEGPH20 compared to placebo when given in combination with standard chemotherapy (Abraxane + Gemzar). Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent.
Be over the age of 18 with a life expectancy of over 3 months
Have stage IV pancreatic ductal adenocarcinoma
Have at least 1 tumor metastasis measurable by CT
Have had previous radiotherapy, surgery, chemotherapy, or investigative therapy for the treatment of metastatic disease
Have a history of stroke or transient ischemic attack